Orogen Royalties Inc

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2020-01-01

Employees: 10K

Market Cap: -

Website: http://www.organon.com

Introduction: Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Clinical Trials

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

Completed

Conditions: Neonates
Pregnancy

Interventions: Biological: Corifollitropin alfa
Biological: GnRH antagonist
Biological: (rec)hCG
Biological: FSH
Drug: Progesterone

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 268

Registration Number: NCT00702234

A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)

Phase 2

Completed

Conditions: In Vitro Fertilization

Interventions: Drug: Org 36286 (corifollitropin alfa)

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-02

Lead Sponsor: Organon and Co

Target Recruit Count: 50

Registration Number: NCT00702351

Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)

Completed

Conditions: In Vitro Fertilization

Interventions: Drug: corifollitropin alfa
Biological: recFSH (follitropin alfa)
Drug: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Drug: human chorion gonadatropin (hCG)
Biological: progesterone
Drug: placebo-recFSH (follitropin alfa)
Drug: placebo-corifollitropin alfa
Biological: open-label recFSH

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 102

Registration Number: NCT00702546

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

Completed

Conditions: Neonates
Pregnancy

Interventions: Drug: Corifollitropin alpha (MK-8962, Org 36286) 150 ug
Drug: Corifollitropin alpha (MK-8962, Org 36286) 100 ug
Drug: Triptorelin
Biological: Recombinant follicle stimulating hormone (recFSH)
Biological: Human chorionic gonadotprophin (hCG).

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 15

Registration Number: NCT00702520

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)

Completed

Conditions: Neonates
Pregnancy

Interventions: Biological: recFSH (follitropin beta)
Drug: Corifollitropin alfa
Drug: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Biological: human chorion gonadotropin (hCG)
Biological: progesterone
Drug: placebo-recFSH (follitropin beta)
Drug: placebo-corifollitropin alfa
Biological: open-label recFSH (follitropin beta)

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 113

Registration Number: NCT00702624

Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)

Completed

Conditions: Pregnancy
Neonates

Interventions: Drug: Org 36286
Drug: recFSH

First Posted Date: 2008-06-20

Last Posted Date: 2022-02-03

Lead Sponsor: Organon and Co

Target Recruit Count: 44

Registration Number: NCT00702988

A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: montelukast
Drug: placebo (unspecified)

First Posted Date: 2008-06-19

Last Posted Date: 2024-08-15

Lead Sponsor: Organon and Co

Target Recruit Count: 500

Registration Number: NCT00700661

Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Phase 3

Completed

Conditions: In Vitro Fertilization

Interventions: Drug: Corifollitropin alfa
Biological: FSH
Biological: GnRH antagonist
Biological: (rec)hCG
Drug: Progesterone

First Posted Date: 2008-06-13

Last Posted Date: 2024-06-18

Lead Sponsor: Organon and Co

Target Recruit Count: 682

Registration Number: NCT00696878

A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)

Phase 3

Completed

Conditions: In Vitro Fertilization

Interventions: Biological: RecFSH / Follitropin beta (Days 1 to 7)
Drug: Corifollitropin alfa
Drug: Placebo RecFSH / follitropin beta
Drug: Placebo Corifollitropin alfa
Biological: RecFSH / Follitropin beta (Days 8 to hCG)
Drug: Ganirelix
Biological: hCG
Biological: Progesterone

First Posted Date: 2008-06-13

Last Posted Date: 2024-06-20

Lead Sponsor: Organon and Co

Target Recruit Count: 1509

Registration Number: NCT00696800

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

Phase 2

Terminated

Conditions: Ovulation Induction

Interventions: Drug: corifollitropin alfa
Biological: human Chorion Gonadotropin (hCG)
Biological: recombinant Follicle Stimulating Hormone (recFSH)
Biological: hCG Bolus injection

First Posted Date: 2008-06-13

Last Posted Date: 2024-06-17

Lead Sponsor: Organon and Co

Target Recruit Count: 8

Registration Number: NCT00697255

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy